Non-coding RNA networks in metabolic dysfunction-associated steatotic liver disease: Mechanisms and therapeutic perspectives

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder worldwide, characterized by complex molecular regulatory networks driving its pathogenesis. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), serve as critical regulators of gene expression and have been increasingly recognized for their pivotal roles in MASLD development. Rather than functioning in isolation, these ncRNAs form intricate regulatory networks that integrate and amplify disease signals across multiple cellular compartments and pathological stages. This review provides a comprehensive overview of how these ncRNA networks orchestrate MASLD progression, focusing on their roles in metabolic dysregulation, inflammation, and fibrosis. We further evaluate the diagnostic potential of circulating ncRNAs as stable, non-invasive biomarkers for disease stratification and monitoring, and discuss emerging therapeutic strategies targeting ncRNAs, including antisense oligonucleotides, synthetic mimics, and advanced delivery platforms such as lipid nanoparticles and engineered exosomes. Despite significant progress, challenges related to delivery efficiency, tissue specificity, and safety remain barriers to clinical translation. By synthesizing current knowledge of ncRNA networks in MASLD and highlighting opportunities for therapeutic intervention, this review provides a roadmap for translating ncRNAs into clinical applications for this increasingly prevalent metabolic liver disease.

Keywords

Metabolic dysfunction-associated steatotic liver disease (MASLD) / Non-coding RNAs (ncRNAs) / Regulatory networks / Biomarkers / Therapeutic strategies

References

[1] Trefts E, Gannon M, Wasserman DH . The liver. Curr Biol. 2017; 27:R1147-R1151. https://doi.org/10.1016/j.cub.2017.09.019.

[2] Michalopoulos GK, Bhushan B . Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol. 2021; 18:40-55. https://doi.org/10.1038/s41575—020—0342—4.

[3] Chien Y, Tsai PH, Lai YH, et al. CircularRNA as novel biomarkers in liver diseases. J Chin Med Assoc. 2020; 83:15-17. https://doi.org/10.1097/JCMA.0000000000000230.

[4] Tilg H, Petta S, Stefan N, Targher G . Metabolic dysfunction—associated steatotic liver disease in adults: a review. JAMA. 2026; 335:163-174. https://doi.org/10.1001/jama.2025.19615.

[5] Ruan S, Huang L, Song J, et al. Global burden trends and forecasts for MAFLD in adolescents and young adults from 1990 to 2021. Sci Rep. 2025; 15:13534. https://doi.org/10.1038/s41598—025—98489—9.

[6] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction—associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73:202-209. https://doi.org/10.1016/j.jhep.2020.03.039.

[7] Targher G, Byrne CD, Tilg H . MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024; 73:691-702. https://doi.org/10.1136/gutjnl—2023—330595.

[8] Zailaie SA, Khoja BB, Siddiqui JJ, et al. Investigating the role of non—coding RNA in non—alcoholic fatty liver disease. Noncoding RNA. 2024;10:10. https://doi.org/10.3390/ncrna10010010.

[9] DiStefano JK, Gerhard GS . Long noncoding RNAs and human liver disease. Annu Rev Pathol. 2022; 17:1-21. https://doi.org/10.1146/annurev—pathol—042320—115255.

[10] Yepmo M, Potier JB, Pinget M, Grabarz A, Bouzakri K, Dumond Bourie A . Discussing the role of circular RNA in the pathogenesis of non—alcoholic fatty liver disease and its complications. Front Endocrinol (Lausanne). 2022; 13:1035159. https://doi.org/10.3389/fendo.2022.1035159.

[11] Palomer X, Wang JR, Tang X, et al. Peroxisome proliferator—activated receptor β/δ: a link between metabolism, inflammation, and fibrosis in metabolic dysfunction—associated steatotic liver disease. Cells. 2026; 15:464. https://doi.org/10.3390/cells15050464.

[12] De A, Chalasani N, Duseja A . Biomarkers in metabolic dysfunction—associated steatotic liver disease. Gastroenterol Clin North Am. 2026; 55:185-202. https://doi.org/10.1016/j.gtc.2025.09.003.

[13] Devasia AG, Ramasamy A, Leo CH . Current therapeutic landscape for metabolic dysfunction—associated steatohepatitis. Int J Mol Sci. 2025; 26:1778. https://doi.org/10.3390/ijms26041778.

[14] Leslie J, Krishnamurthy KA, Gopalsamy IK, et al. Metabolic dysfunction—associated steatotic liver disease and steatohepatitis—associated hepatocarcinoma preclinical models. Nat Rev Gastroenterol Hepatol. 2026; 23:286-317. https://doi.org/10.1038/s41575—025—01162—9.

[15] Friedman SL, Neuschwander—Tetri BA, Rinella M, Sanyal AJ . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24:908-922. https://doi.org/10.1038/s41591—018—0104—9.

[16] Jin S, Zhu L, Bao R, et al. Helicobacter hepaticus promotes hepatic steatosis through CdtB—induced mitochondrial stress and lipid metabolism reprogramming. Nat Commun. 2025; 16:7954. https://doi.org/10.1038/s41467—025—63351—z.

[17] Jara M, Norlin J, Kjær MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction—associated steatohepatitis. Nat Med. 2025; 31:3128-3140. https://doi.org/10.1038/s41591—025—03799—0.

[18] Horn P, Tacke F . Metabolic reprogramming in liver fibrosis. Cell Metab. 2024; 36:1439-1455. https://doi.org/10.1016/j.cmet.2024.05.003.

[19] He W, Huang C, Zhang X, et al. Identification of transcriptomic signatures and crucial pathways involved in non—alcoholic steatohepatitis. Endocrine. 2021; 73:52-64. https://doi.org/10.1007/s12020—021—02716—y.

[20] Bhattacharya I, Maity DK, Kumar A, et al. Beyond obesity: lean metabolic dysfunction—associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement. Naunyn—Schmiedebergs Arch Pharmacol. 2025; 398:13647-13665. https://doi.org/10.1007/s00210—025—04257—x.

[21] Bauer KC, Littlejohn PT, Ayala V, Creus—Cuadros A, Finlay BB . Nonalcoholic fatty liver disease and the gut—liver axis: exploring an undernutrition perspective. Gastroenterology. 2022; 162:1858-1875 (e2). https://doi.org/10.1053/j.gastro.2022.01.058.

[22] Locatelli C, Luz K, Andrade SF, et al. MicroRNAs as key regulators in the progression of metabolic dysfunction—associated steatotic liver disease: a bioinformatics analysis. Biomedicines. 2026; 14:120. https://doi.org/10.3390/biomedicines14010120.

[23] Feng T, Liang Y, Sun L, et al. Regulation of hepatic lipid metabolism by intestine epithelium—derived exosomes. Life Metab. 2023; 2:load044. https://doi.org/10.1093/lifemeta/load044.

[24] Gofton C, Upendran Y, Zheng MH, George J . MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023; 29:S17-S31. https://doi.org/10.3350/cmh.2022.0367.

[25] Castera L, Friedrich—Rust M, Loomba R . Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156:1264-1281 (e4). https://doi.org/10.1053/j.gastro.2018.12.036.

[26] Sanyal AJ, Shankar SS, Yates KP, et al. Diagnostic performance of circulating biomarkers for non—alcoholic steatohepatitis. Nat Med. 2023; 29:2656-2664. https://doi.org/10.1038/s41591—023—02539—6.

[27] Vilar—Gomez E, Martinez—Perez Y, Calzadilla—Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149:367 (e5). https://doi.org/10.1053/j.gastro.2015.04.005.

[28] Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015; 149:379 (e16). https://doi.org/10.1053/j.gastro.2015.04.014.

[29] Johnson—Moore T, Simmons D, Okafor A, Washington D, Baskaran P . Resmetirom and beyond: a new era in MASLD therapeutics. Liver Res. 2025; 9:362-364. https://doi.org/10.1016/j.livres.2025.10.004.

[30] Knorr JP, Reese R, Serbantez M, Lin KP . Metabolic dysfunction—associated steatotic liver disease (MASLD): integrating metabolic and hepatic management into pharmacy practice. Am J Health Syst Pharm. https://doi.org/10.1093/ajhp/zxag095. Published online March 25, 2026.

[31] Suresh MG, Mohamed S, Geetha HS, et al. Metabolic dysfunction—associated steatotic liver disease and type 2 diabetes: pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes. 2026; 17:113149. https://doi.org/10.4239/wjd.v17.i2.113149.

[32] Kim Y, Rydqvist P, Ramezani T, et al. Metabolic dysfunction—associated steatohepatitis diagnosis and management in Germany: insights from an expert consensus panel. Liver Int. 2025; 45:e70225. https://doi.org/10.1111/liv.70225.

[33] Kozomara A, Birgaoanu M, Griffiths—Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019; 47:D155-D162. https://doi.org/10.1093/nar/gky1141.

[34] Friedman RC, Farh KK, Burge CB, Bartel DP . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19:92-105. https://doi.org/10.1101/gr.082701.108.

[35] Macvanin M, Obradovic M, Zafirovic S, Stanimirovic J, Isenovic ER . The role of miRNAs in metabolic diseases. Curr Med Chem. 2023; 30:1922-1944. https://doi.org/10.2174/0929867329666220801161536.

[36] Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008; 22:3172-3183. https://doi.org/10.1101/gad.1706508.

[37] Guo H, Ingolia NT, Weissman JS, Bartel DP . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466:835-840. https://doi.org/10.1038/nature09267.

[38] O’Connell RM, Rao DS, Baltimore D . microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012; 30:295-312. https://doi.org/10.1146/annurev—immunol—020711—075013.

[39] Leung AK, Sharp PA . MicroRNA functions in stress responses. Mol Cell. 2010; 40:205-215. https://doi.org/10.1016/j.molcel.2010.09.027.

[40] Quinn JJ, Chang HY . Unique features of long non—coding RNA biogenesis and function. Nat Rev Genet. 2016; 17:47-62. https://doi.org/10.1038/nrg.2015.10.

[41] Mattick JS, Amaral PP, Carninci P, et al. Long non—coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24:430-447. https://doi.org/10.1038/s41580—022—00566—8.

[42] Gupta RA, Shah N, Wang KC, et al. Long non—coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1076. https://doi.org/10.1038/nature08975.

[43] Statello L, Guo CJ, Chen LL, Huarte M . Gene regulation by long non—coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021; 22:96-118. https://doi.org/10.1038/s41580—020—00315—9.

[44] Cheng Y, He RR, Jiang J, et al. Noncanonical open reading frames from lncRNAs encode functional micropeptides that help shape agronomic traits in rice. Dev Cell. 2026; 61:919-935 (e6). https://doi.org/10.1016/j.devcel.2026.01.010.

[45] Wanowska E, Kubiak M, Makałowska I, Szcześniak MW . A chromatin—associated splicing isoform of OIP5—AS1 acts in cis to regulate the OIP5 oncogene. RNA Biol. 2021; 18:1834-1845. https://doi.org/10.1080/15476286.2021.1871816.

[46] O’Leary E, Jiang Y, Kristensen LS, Hansen TB, Kjems J . The therapeutic potential of circular RNAs. Nat Rev Genet. 2025; 26:230-244. https://doi.org/10.1038/s41576—024—00806—x.

[47] Chen LL . The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020; 21:475-490. https://doi.org/10.1038/s41580—020—0243—y.

[48] Baiddou C, Knidiri M, Ghazi B, Abu Obaid A, Hamdi S, Errafii K . The circular RNA landscape: biogenesis, functions, identification pipelines, and biomedical applications. Noncoding RNA Res. 2026; 18:39-51. https://doi.org/10.1016/j.ncrna.2025.12.005.

[49] Zhang X, Wang C, Xia S, et al. The emerging role of snoRNAs in human disease. Genes Dis. 2022; 10:2064-2081. https://doi.org/10.1016/j.gendis.2022.11.018.

[50] Zhang C, Yang K, Zhao Z, Feng M, Song L, Xu Z . piRNA: molecular mechanisms from germline silencing to somatic regulation and roles in disease. Int J Mol Sci. 2026; 27:2685. https://doi.org/10.3390/ijms27062685.

[51] Wang Y, Song X, Ma G, et al. tRNA—derived small RNAs in pulmonary diseases: regulatory functions and clinical prospects. Pharmacol Res. 2026; 226:108153. https://doi.org/10.1016/j.phrs.2026.108153.

[52] Li YL, Xu Y, Guan ZW, Meng L, Qu Y, Qiu J . Biological function of tRNA—derived small RNA and its expression and clinical significance in liver diseases. J Clin Hepatol. 2025; 41:1227-1234. https://doi.org/10.12449/jch250634.

[53] Lucaciu RL, Orasan OH, Hangan AC, et al. miRNAs, lncRNAs, circRNAs and piRNAs in nonalcoholic fatty liver disease: past, present and future. Int J Mol Sci. 2025; 26:10402. https://doi.org/10.3390/ijms262110402.

[54] Sletten AC, Davidson JW, Yagabasan B, et al. Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis. Nat Commun. 2021; 12:5214. https://doi.org/10.1038/s41467—021—25457—y.

[55] Dunkel H, Jensen LR, Sperling F, et al. Cross—organ communication based on non—coding RNA networks leads to cognitive dysfunction in mice. Neurobiol Dis. 2026; 221:107319. https://doi.org/10.1016/j.nbd.2026.107319.

[56] Yin X, Du Z, Jiang S, et al. RNA regulatory networks: key hubs in the panorama of cancer and emerging therapeutic targets. MedComm (2020). 2026; 7:e70586. https://doi.org/10.1002/mco2.70586.

[57] Zeng QM, Hu T, Jiang W, et al. CircZBTB46 alleviates metabolic dysfunction—associated steatotic liver disease by targeting miRNA—326/FGF1 axis. Cell Death Discov. 2026; 12:17. https://doi.org/10.1038/s41420—025—02833—x.

[58] Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction—associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025; 11:14. https://doi.org/10.1038/s41572—025—00599—1.

[59] Su Q, Kumar V, Sud N, Mahato RI . MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018; 129:54-63. https://doi.org/10.1016/j.addr.2018.01.009.

[60] Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti—inflammatory, and anti—tumorigenic functions of miR—122 in liver. J Clin Invest. 2012; 122:2871-2883. https://doi.org/10.1172/jci63539.

[61] Wang X, He Y, Mackowiak B, Gao B . MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021; 70:784-795. https://doi.org/10.1136/gutjnl—2020—322526.

[62] Zhang X, Zhao H, Sheng Q, et al. Regulation of microRNA—33, SREBP and ABCA1 genes in a mouse model of high cholesterol. Arch Anim Breed. 2021; 64:103-108. https://doi.org/10.5194/aab—64—103—2021.

[63] Horie T, Nishino T, Baba O, et al. MicroRNA—33 regulates sterol regulatory element—binding protein 1 expression in mice. Nat Commun. 2013; 4:2883. https://doi.org/10.1038/ncomms3883.

[64] Näär AM . miR—33: a metabolic conundrum. Trends Endocrinol Metab. 2018; 29:667-668. https://doi.org/10.1016/j.tem.2018.04.004.

[65] Zayed RK, Sayed NH, Shaker OG, Seleem MM, Darwish HA, Shaheen A . Role of lncRNAs H19, KCNQ1OT1 and SRA in relation to peroxisome proliferator—activated receptor gamma in the occurrence and progression of non—alcoholic fatty pancreas disease in obese and non—obese Egyptian patients. Int J Biol Macromol. 2025; 331:148270. https://doi.org/10.1016/j.ijbiomac.2025.148270.

[66] Chen G, Yu D, Nian X, et al. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci Rep. 2016; 6:35531. https://doi.org/10.1038/srep35531.

[67] Wu LF, Zhou ZJ, Zeng YH, Yang SL, Zhang QY . Circular RNA RRM2 alleviates metabolic dysfunction—associated steatotic liver disease by targeting miR—142—5p to increase NRG1 expression. Am J Physiol Gastrointest Liver Physiol. 2024; 327:G485-G498. https://doi.org/10.1152/ajpgi.00255.2023.

[68] Wang Y, Tian X, Wang Z, et al. A novel peptide encoded by circ—SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac—mediated CD36 transcription in NAFLD. Clin Transl Med. 2024; 14:e1801. https://doi.org/10.1002/ctm2.1801.

[69] Hanin G, Yayon N, Tzur Y, et al. miRNA—132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 2018; 67:1124-1134. https://doi.org/10.1136/gutjnl—2016—312869.

[70] Gao F, Ma Y, Yu C, Duan Q . miR—125b—5p regulates FFA—induced hepatic steatosis in L02 cells by targeting estrogen—related receptor alpha. Gene. 2025; 959:149419. https://doi.org/10.1016/j.gene.2025.149419.

[71] Ma L, Song H, Zhang CY, Hou D . MiR—192—5p ameliorates hepatic lipid metabolism in non—alcoholic fatty liver disease by targeting Yy1. Biomolecules. 2023; 14:34. https://doi.org/10.3390/biom14010034.

[72] Lin HY, Wang FS, Yang YL, Huang YH . MicroRNA—29a suppresses CD36 to ameliorate high fat diet—induced steatohepatitis and liver fibrosis in mice. Cells. 2019; 8:1298. https://doi.org/10.3390/cells8101298.

[73] Wang L, Jia G, Fu R, et al. Hepatic miR—363 promotes nonalcoholic fatty liver disease by suppressing INSIG1. J Nutr Biochem. 2024; 134:109717. https://doi.org/10.1016/j.jnutbio.2024.109717.

[74] Lee YH, Lee J, Jeong J, et al. Hepatic miR—93 promotes the pathogenesis of metabolic dysfunction—associated steatotic liver disease by suppressing SIRT1. Metabolism. 2025; 169:156266. https://doi.org/10.1016/j.metabol.2025.156266.

[75] Chen X, Ma H, Gao Y, et al. Long non—coding RNA AC012668 suppresses non—alcoholic fatty liver disease by competing for microRNA miR—380—5p with lipoprotein—related protein LRP2. Bioengineered. 2021; 12:6738-6747. https://doi.org/10.1080/21655979.2021.1960463.

[76] Wang P, Wang X, He D, Zhuang C . LncRNA AK142643 promotes hepatic lipid accumulation by upregulating CD36 via interacting with IGF2BP2. Gene. 2023; 887:147747. https://doi.org/10.1016/j.gene.2023.147747.

[77] Huang F, Liu H, Lei Z, et al. Long noncoding RNA CCAT1 inhibits miR—613 to promote nonalcoholic fatty liver disease via increasing LXRα transcription. J Cell Physiol. 2020; 235:9819-9833. https://doi.org/10.1002/jcp.29795.

[78] Xu S, Wang Y, Li Z, Hua Q, Jiang M, Fan X . LncRNA GAS5 knockdown mitigates hepatic lipid accumulation via regulating miR—26a—5p/PDE4B to activate cAMP/CREB pathway. Front Endocrinol (Lausanne). 2022; 13:889858. https://doi.org/10.3389/fendo.2022.889858.

[79] Cui J, Wang Y, Xue H . Long non—coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA—29a—3p/NOTCH2 axis. Bioengineered. 2022; 13:8370-8381. https://doi.org/10.1080/21655979.2022.2026858.

[80] Li T, Huang X, Yue Z, Meng L, Hu Y . Knockdown of long non—coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non—alcoholic fatty liver disease. Cell Biochem Funct. 2020; 38:839-846. https://doi.org/10.1002/cbf.3495.

[81] Ma M, Duan R, Shen L, et al. The lncRNA Gm15622 stimulates SREBP—1c expression and hepatic lipid accumulation by sponging the miR—742—3p in mice. J Lipid Res. 2020; 61:1052-1064. https://doi.org/10.1194/jlr.RA120000664.

[82] Di Mauro S, Salomone F, Scamporrino A, et al. Coffee restores expression of lncRNAs involved in steatosis and fibrosis in a mouse model of NAFLD. Nutrients. 2021; 13:2952. https://doi.org/10.3390/nu13092952.

[83] Wang H, Cao Y, Shu L, et al. Long non—coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med. 2020; 24:1399-1412. https://doi.org/10.1111/jcmm.14818.

[84] El Sobky SA, Aboud NK, El Assaly NM, Fawzy IO, El—Ekiaby N, Abdelaziz AI . Regulation of lipid droplet (LD) formation in hepatocytes via regulation of SREBP1c by non—coding RNAs. Front Med (Lausanne). 2022; 9:903856. https://doi.org/10.3389/fmed.2022.903856.

[85] Liu J, Tang T, Wang GD, Liu B . LncRNA—H19 promotes hepatic lipogenesis by directly regulating miR—130a/PPARγ axis in non—alcoholic fatty liver disease. Biosci Rep. 2019; 39:BSR20181722. https://doi.org/10.1042/BSR20181722.

[86] Guo B, Cheng Y, Yao L, et al. LncRNA HOTAIR regulates the lipid accumulation in non—alcoholic fatty liver disease via miR—130b—3p/ROCK1 axis. Cell Signal. 2022; 90:110190. https://doi.org/10.1016/j.cellsig.2021.110190.

[87] Chi Y, Gong Z, Xin H, Wang Z, Liu Z . Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. J Transl Med. 2020; 18:126. https://doi.org/10.1186/s12967—020—02225—y.

[88] Bu FT, Wang A, Zhu Y, et al. LncRNA NEAT1: shedding light on mechanisms and opportunities in liver diseases. Liver Int. 2020; 40:2612-2626. https://doi.org/10.1111/liv.14629.

[89] Ding Y, Zheng S, Fu XN, Ma C, Juan Y . LncRNA SNHG4 regulates lipid metabolism and inflammation in non—alcoholic fatty liver disease by targeting miR—34b—5p/XIAP axis. Turk J Gastroenterol. 2025; 36:629-640. https://doi.org/10.5152/tjg.2025.24191.

[90] Chen X, Tan QQ, Tan XR, Li SJ, Zhang XX . Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR—206. Cell Death Dis. 2021; 12:809. https://doi.org/10.1038/s41419—021—04090—z.

[91] Yang W, Zhao J, Zhao Y, et al. Hsa_circ_0048179 attenuates free fatty acid—induced steatosis via hsa_circ_0048179/miR—188—3p/GPX4 signaling. Aging (Albany NY). 2020; 12:23996-24008. https://doi.org/10.18632/aging.104081.

[92] Chen Z, Tian R, She Z, Cai J, Li H . Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020; 152:116-141. https://doi.org/10.1016/j.freeradbiomed.2020.02.025.

[93] Hochreuter MY, Dall M, Treebak JT, Barrès R . MicroRNAs in non—alcoholic fatty liver disease: progress and perspectives. Mol Metab. 2022; 65:101581. https://doi.org/10.1016/j.molmet.2022.101581.

[94] Fu T, Choi SE, Kim DH, et al. Aberrantly elevated microRNA—34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β—Klotho. Proc Natl Acad Sci U S A. 2012; 109:16137-16142. https://doi.org/10.1073/pnas.1205951109.

[95] Feili X, Wu S, Ye W, Tu J, Lou L . MicroRNA—34a—5p inhibits liver fibrosis by regulating TGF—β1/Smad3 pathway in hepatic stellate cells. Cell Biol Int. 2018; 42:1370-1376. https://doi.org/10.1002/cbin.11022.

[96] Harrison SA, Ratziu V, Boursier J, et al. A blood—based biomarker panel (NIS4) for non—invasive diagnosis of non—alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020; 5:970-985. https://doi.org/10.1016/s2468—1253(20)30252—1.

[97] Zhao Q, Liu J, Deng H, et al. Targeting mitochondria—located circRNA SCAR alleviates NASH via reducing mROS output. Cell. 2020; 183:76-93 (e22). https://doi.org/10.1016/j.cell.2020.08.009.

[98] Ye L, Zhao D, Xu Y, et al. LncRNA—Gm9795 promotes inflammation in non—alcoholic steatohepatitis via NF—κB/JNK pathway by endoplasmic reticulum stress. J Transl Med. 2021; 19:101. https://doi.org/10.1186/s12967—021—02769—7.

[99] Xu H, Tian Y, Tang D, et al. An endoplasmic reticulum stress—microRNA—26a feedback circuit in NAFLD. Hepatology. 2021; 73:1327-1345. https://doi.org/10.1002/hep.31428.

[100] Teimouri M, Hosseini H, Shabani M, Koushki M, Noorbakhsh F, Meshkani R . Inhibiting miR—27a and miR—142—5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway. IUBMB Life. 2020; 72:361-372. https://doi.org/10.1002/iub.2221.

[101] Zhang Y, Wang C, Lu J, et al. Targeting of miR—96—5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr—/— mice via p66shc/cytochrome C cascade. Aging (Albany NY). 2020; 12:2049-2069. https://doi.org/10.18632/aging.102721.

[102] Chen Y, Chen X, Gao J, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl—Sirt1 pathway. FASEB J. 2019; 33:11411-11419. https://doi.org/10.1096/fj.201900643RRR.

[103] Wang L, Zhang N, Wang Z, Ai DM, Cao ZY, Pan HP . Decreased MiR—155 level in the peripheral blood of non—alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity. Cell Physiol Biochem. 2016; 39:2239-2248. https://doi.org/10.1159/000447917.

[104] Torres JL, Novo—Veleiro I, Manzanedo L, et al. Role of microRNAs in alcohol—induced liver disorders and non—alcoholic fatty liver disease. World J Gastroenterol. 2018; 24:4104-4118. https://doi.org/10.3748/wjg.v24.i36.4104.

[105] Bala S, Ganz M, Babuta M, et al. Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR—155 deficient mice in a high fat—cholesterol—sugar diet—induced model of NASH. Lab Invest. 2021; 101:1540-1549. https://doi.org/10.1038/s41374—021—00626—1.

[106] He Y, Rodrigues RM, Wang X, et al. Neutrophil—to—hepatocyte communication via LDLR—dependent miR—223—enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest. 2021; 131:e141513. https://doi.org/10.1172/jci141513.

[107] He Y, Hwang S, Cai Y, et al. MicroRNA—223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology. 2019; 70:1150-1167. https://doi.org/10.1002/hep.30645.

[108] Yan C, Chen J, Chen N . Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP—1c protein stability. Sci Rep. 2016; 6:22640. https://doi.org/10.1038/srep22640.

[109] Leti F, Legendre C, Still CD, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res. 2017; 190:25-39 (e21). https://doi.org/10.1016/j.trsl.2017.09.001.

[110] Chen F, Xing Y, Chen Z, et al. Competitive adsorption of microRNA—532—3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non—alcoholic fatty hepatocytes. Eur J Med Res. 2024; 29:250. https://doi.org/10.1186/s40001—024—01817—4.

[111] Zhang Q, Yu K, Cao Y, Luo Y, Liu Y, Zhao C . miR—125b promotes the NF—κB—mediated inflammatory response in NAFLD via directly targeting TNFAIP3. Life Sci. 2021; 270:119071. https://doi.org/10.1016/j.lfs.2021.119071.

[112] Liu XL, Pan Q, Cao HX, et al. Lipotoxic hepatocyte—derived exosomal microRNA 192—5p activates macrophages through Rictor/Akt/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology. 2020; 72:454-469. https://doi.org/10.1002/hep.31050.

[113] Zhang T, Hu J, Wang X, et al. MicroRNA—378 promotes hepatic inflammation and fibrosis via modulation of the NF—κB—TNFα pathway. J Hepatol. 2019; 70:87-96. https://doi.org/10.1016/j.jhep.2018.08.026.

[114] Yang L, Liu S, He Y, et al. Exosomes regulate SIRT3—related autophagy by delivering miR—421 to regulate macrophage polarization and participate in OSA—related NAFLD. J Transl Med. 2024; 22:475. https://doi.org/10.1186/s12967—024—05283—8.

[115] Hur W, Lee JH, Kim SW, et al. Downregulation of microRNA—451 in non—alcoholic steatohepatitis inhibits fatty acid—induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol. 2015; 64:265-276. https://doi.org/10.1016/j.biocel.2015.04.016.

[116] Chen T, Meng Y, Zhou Z, et al. GAS5 protects against nonalcoholic fatty liver disease via miR—28a—5p/MARCH7/NLRP3 axis—mediated pyroptosis. Cell Death Differ. 2023; 30:1829-1848. https://doi.org/10.1038/s41418—023—01183—4.

[117] Guo B, Yan S, Zhai L, Cheng Y . LncRNA HOTAIR accelerates free fatty acid—induced inflammatory response in HepG2 cells by recruiting SRSF1 to stabilize MLXIPL mRNA. Cytotechnology. 2024; 76:259-269. https://doi.org/10.1007/s10616—023—00614—x.

[118] Atanasovska B, Rensen SS, Marsman G, et al. Long non—coding RNAs involved in progression of non—alcoholic fatty liver disease to steatohepatitis. Cells. 2021; 10:1883. https://doi.org/10.3390/cells10081883.

[119] Lin Y, Wang S, Gao L, et al. Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice. Theranostics. 2021; 11:426-444. https://doi.org/10.7150/thno.50281.

[120] Hammerich L, Tacke F . Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023; 20:633-646. https://doi.org/10.1038/s41575—023—00807—x.

[121] Atic AI, Thiele M, Munk A, Dalgaard LT . Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol. 2023; 324:C588-C602. https://doi.org/10.1152/ajpcell.00253.2022.

[122] Liu CH, Ampuero J, Gil—Gómez A, et al. miRNAs in patients with non—alcoholic fatty liver disease: a systematic review and meta—analysis. J Hepatol. 2018; 69:1335-1348. https://doi.org/10.1016/j.jhep.2018.08.008.

[123] Zhang Z, Zha Y, Hu W, et al. The autoregulatory feedback loop of microRNA—21/programmed cell death protein 4/activation protein—1 (MiR—21/PDCD4/AP—1) as a driving force for hepatic fibrosis development. J Biol Chem. 2013; 288:37082-37093. https://doi.org/10.1074/jbc.M113.517953.

[124] Wang XM, Wang XY, Huang YM, et al. Role and mechanisms of action of microRNA—21 as regards the regulation of the WNT/β—catenin signaling pathway in the pathogenesis of non—alcoholic fatty liver disease. Int J Mol Med. 2019; 44:2201-2212. https://doi.org/10.3892/ijmm.2019.4375.

[125] Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ . LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR—21 with LRP6. Metabolism. 2019; 94:1-8. https://doi.org/10.1016/j.metabol.2019.01.018.

[126] Jin SS, Lin XF, Zheng JZ, Wang Q, Guan HQ . lncRNA NEAT1 regulates fibrosis and inflammatory response induced by nonalcoholic fatty liver by regulating miR—506/GLI3. Eur Cytokine Netw. 2019; 30:98-106. https://doi.org/10.1684/ecn.2019.0432.

[127] Jin SS, Lin CJ, Lin XF, Zheng JZ, Guan HQ . Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR—139—5p/c—Jun/SREBP—1c pathway. Ann Hepatol. 2022; 27:100584. https://doi.org/10.1016/j.aohep.2021.100584.

[128] Chen C, Li H, Wang X, Wang L, Zeng Q . Lnc—LFAR1 affects intrahepatic cholangiocarcinoma proliferation, invasion, and EMT by regulating the TGFβ/Smad signaling pathway. Int J Clin Exp Pathol. 2019; 12:2455-2461.

[129] Zhong J, Zhang Z, Xiao L, et al. Circular RNA encoding relaxin—2 as a potential therapy for liver fibrosis. Mol Ther Nucleic Acids. 2026; 37:102807. https://doi.org/10.1016/j.omtn.2025.102807.

[130] Wang Y, Du J, Niu X, et al. MiR—130a—3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2. Cell Death Dis. 2017; 8:e2792. https://doi.org/10.1038/cddis.2017.10.

[131] Markovic J, Sharma AD, Balakrishnan A . MicroRNA—221: a fine tuner and potential biomarker of chronic liver injury. Cells. 2020; 9:1767. https://doi.org/10.3390/cells9081767.

[132] Hou X, Yin S, Ren R, et al. Myeloid—cell—specific IL—6 signaling promotes microRNA—223—enriched exosome production to attenuate NAFLD—associated fibrosis. Hepatology. 2021; 74:116-132. https://doi.org/10.1002/hep.31658.

[133] Shen X, Guo H, Xu J, Wang J . Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019; 234:18169-18179. https://doi.org/10.1002/jcp.28450.

[134] Rusman RD, Akil F, Parewangi ML, et al. Gut microbiota and metabolic—associated steatosis liver disease: unveiling mechanisms and opportunities for therapeutic intervention. World J Exp Med. 2025; 15:107316. https://doi.org/10.5493/wjem.v15.i4.107316.

[135] Yamin M, Alsahafi N, Abdulal RH, Asad M, Bosaeed M, Zohaib A . Non—coding RNAs in the viral host—pathogen interaction: molecular regulation and therapeutic potential. Front Cell Infect Microbiol. 2025; 15:1734182. https://doi.org/10.3389/fcimb.2025.1734182.

[136] Asero C, Franzè MS, Cacciola I, Gangemi S . MASLD under the microscope: how microRNAs and microbiota shape hepatic metabolic disease progression. Int J Mol Sci. 2025; 26:8633. https://doi.org/10.3390/ijms26178633.

[137] Hou Q, Huang Y, Wang Y, et al. Lactobacillus casei LC01 regulates intestinal epithelial permeability through miR—144 targeting of OCLN and ZO1. J Microbiol Biotechnol. 2020; 30:1480-1487. https://doi.org/10.4014/jmb.2002.02059.

[138] Behrouzi A, Ashrafian F, Mazaheri H, et al. The importance of interaction between MicroRNAs and gut microbiota in several pathways. Microb Pathog. 2020; 144:104200. https://doi.org/10.1016/j.micpath.2020.104200.

[139] Zhang F, Liu R, Xu T, Xu W, Huang K, He X . Broccoli—derived exosome—like nanoparticles alleviates metabolic dysfunction—associated steatotic liver disease through modulating the gut—liver axis. Nutrients. 2026; 18:953. https://doi.org/10.3390/nu18060953.

[140] Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT . MicroRNAs are transported in plasma and delivered to recipient cells by high—density lipoproteins. Nat Cell Biol. 2011; 13:423-433. https://doi.org/10.1038/ncb2210.

[141] van Zonneveld AJ, Zhao Q, Rotmans JI, Bijkerk R . Circulating non—coding RNAs in chronic kidney disease and its complications. Nat Rev Nephrol. 2023; 19:573-586. https://doi.org/10.1038/s41581—023—00725—w.

[142] Wang Z, Kim SY, Tu W, et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell Metab. 2023; 35:1209-1226 (e13). https://doi.org/10.1016/j.cmet.2023.04.013.

[143] Samy AM, Kandeil MA, Sabry D, Abdel—Ghany AA, Mahmoud MO . Exosomal miR—122, miR—128, miR—200, miR—298, and miR—342 as novel diagnostic biomarkers in NAFL/NASH: impact of LPS/TLR—4/FoxO3 pathway. Arch Pharm (Weinheim). 2024; 357:e202300631. https://doi.org/10.1002/ardp.202300631.

[144] Ying W, Riopel M, Bandyopadhyay G, et al. Adipose tissue macrophage—derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell. 2017; 171:372-384 (e12). https://doi.org/10.1016/j.cell.2017.08.035.

[145] Chai C, Rivkin M, Berkovits L, et al. Metabolic circuit involving free fatty acids, microRNA 122, and triglyceride synthesis in liver and muscle tissues. Gastroenterology. 2017; 153:1404-1415. https://doi.org/10.1053/j.gastro.2017.08.013.

[146] Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkowicz A, Dulak J . MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem. 2011; 401:2051-2061. https://doi.org/10.1007/s00216—011—5001—8.

[147] Cortez MA, Bueso—Ramos C, Ferdin J, Lopez—Berestein G, Sood AK, Calin GA . MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8:467-477. https://doi.org/10.1038/nrclinonc.2011.76.

[148] Li Y, Luan Y, Li J, et al. Exosomal miR—199a—5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. Hepatol Int. 2020; 14:1057-1074. https://doi.org/10.1007/s12072—020—10096—0.

[149] Zeng Q, Liu CH, Ampuero J, et al. Circular RNAs in non—alcoholic fatty liver disease: functions and clinical significance. RNA Biol. 2024; 21:1-15. https://doi.org/10.1080/15476286.2023.2290769.

[150] Lennox KA, Behlke MA . Cellular localization of long non—coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016; 44:863-877. https://doi.org/10.1093/nar/gkv1206.

[151] Jin X, Gao J, Zheng R, et al. Antagonizing circRNA_002581—miR—122—CPEB1 axis alleviates NASH through restoring PTEN—AMPK—mTOR pathway regulated autophagy. Cell Death Dis. 2020; 11:123. https://doi.org/10.1038/s41419—020—2293—7.

[152] Wang Y, Wang J, Zhou Z, et al. A read—through circular RNA RCRIN inhibits metabolic dysfunction—associated steatotic liver disease. J Hepatol. 2025; 82:1068-1079. https://doi.org/10.1016/j.jhep.2024.11.052.

[153] Li J, Qi J, Tang Y, et al. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR—106a—5p/miR—320a and ABCA1/CPT1 axis. J Nanobiotechnology. 2021; 19:363. https://doi.org/10.1186/s12951—021—01108—8.

[154] Roberts TC, Langer R, Wood MJA . Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020; 19:673-694. https://doi.org/10.1038/s41573—020—0075—7.

[155] Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ . Comparison of DLin—MC3—DMA and ALC—0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol Pharm. 2022; 19:2175-2182. https://doi.org/10.1021/acs.molpharmaceut.2c00033.

[156] Tam YY, Chen S, Cullis PR . Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013; 5:498-507. https://doi.org/10.3390/pharmaceutics5030498.

[157] Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017; 376:1430-1440. https://doi.org/10.1056/NEJMoa1615758.

[158] Kalluri R, LeBleu VS . The biology, function, and biomedical applications of exosomes. Science. 2020; 367:eaau6977. https://doi.org/10.1126/science.aau6977.

[159] Zhang H, Xing J, Sun M, et al. Engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Biomaterials. 2026; 324:123510. https://doi.org/10.1016/j.biomaterials.2025.123510.

[160] Liu Y, Chen S, Huang H, et al. Ligand—tethered extracellular vesicles mediated RNA therapy for liver fibrosis. Adv Healthc Mater. 2025; 14:e2403068. https://doi.org/10.1002/adhm.202403068.

[161] Li Z, Ding H, Liu X, et al. miRNA regulatory networks as precision diagnostic and therapeutic targets in pulmonary arterial hypertension: from molecular cascades to clinical translation. Am J Cardiovasc Dis. 2025; 15:335-356. https://doi.org/10.62347/rgty8619.

[162] Mastoridou EM, Goussia AC, Kataki A, et al. The interplay between cellular senescence and lipid metabolism in the progression of metabolic dysfunction—associated steatotic liver disease (MASLD). Int J Mol Sci. 2026; 27:1066. https://doi.org/10.3390/ijms27021066.

[163] Huang XL, Chen WH, Ding M, Song YM, Zheng YW . The revolutionary role of machine learning in predicting, diagnosing, and treating liver disease. Liver Res. 2025; 9:249-251. https://doi.org/10.1016/j.livres.2025.04.001.

[164] Zhang H, Wang Y, Pan Z, et al. ncRNAInter: a novel strategy based on graph neural network to discover interactions between lncRNA and miRNA. Brief Bioinform. 2022; 23:bbac411. https://doi.org/10.1093/bib/bbac411.